Is vedolizumab effective for preventing lower GI acute GvHD?

During the 2023 Tandem Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, the GvHD Hub was pleased to speak to Yi-Bin Chen, Massachusetts General Hospital, Boston, US. We asked, Is vedolizumab effective for preventing lower gastrointestinal (GI) acute graft-versus-host disease (aGvHD)?

Chen begins by summarizing the justifications, methods, and data from the phase III randomized, double blind, placebo-controlled GRAPHITE trial of vedolizumab. GRAPHITE was a prospective large cohort trial with a primary endpoint of lower GI aGvHD-free survival by Day 180. Chen explains the trials clinical significance, highlighting overall survival, relapse free survival, and safety.

Chen concludes by discussing the impact of current clinical trials on future treatment and prevention strategies for GvHD, as well as the impact of new interventions on patient populations.